XNK Therapeutics has announced that the first-in-human Phase I study ACP-001, performed at the Karolinska University Hospital, has been published in Cell Reports Medicine.
The study demonstrates that XNK’s autologous natural killer (NK) cell-based immunotherapy is feasible, states the company. Furthermore, it shows a good safety profile and promising efficacy data as consolidation treatment following autologous stem cell transplantation in patients newly diagnosed with multiple myeloma, the company continues.
“XNK is focused on the clinical development of autologous natural killer cell-based products using its proprietary technology platform. Having this study completed is an important milestone in XNK’s clinical development,” says Johan Aschan, CMO of XNK Therapeutics.
An open, single-arm, triple escalating dose/patient clinical trial
The study was performed at the Karolinska University Hospital, Stockholm, Sweden, together with scientists at Karolinska Institutet, in a setting of consolidation treatment following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. The study was an open, single-arm, triple escalating dose/patient clinical trial with the primary objective of studying the product’s safety and tolerability.
In the study, the therapy showed a good safety profile, no observed serious adverse events and promising efficacy data with objective detectable responses in all patients with measurable disease. XNK Therapeutics is continuing its clinical development in multiple myeloma. Its leading investigational drug candidate is currently studied in a randomized Phase II clinical trial (ISA-HC-NK).
Photo of Johan Aschan: XNK Therapeutics